ECSP109882A - Derivados de 1-cianociclopropilo como inhibidores de la catepsina k - Google Patents

Derivados de 1-cianociclopropilo como inhibidores de la catepsina k

Info

Publication number
ECSP109882A
ECSP109882A EC2010009882A ECSP109882A ECSP109882A EC SP109882 A ECSP109882 A EC SP109882A EC 2010009882 A EC2010009882 A EC 2010009882A EC SP109882 A ECSP109882 A EC SP109882A EC SP109882 A ECSP109882 A EC SP109882A
Authority
EC
Ecuador
Prior art keywords
inhibitors
cyanociclopropilo
catepsin
derivatives
compounds
Prior art date
Application number
EC2010009882A
Other languages
English (en)
Inventor
Nicola Heron
Alexander Graham Dossetter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP109882A publication Critical patent/ECSP109882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I) y composiciones para tratar enfermedades asociadas con la actividad de cisteína proteasas. Los compuestos son inhibidores reversibles de cisteína proteasas, incluidas las catepsinas B, K, C, F, H, L, O, S, W y X. Son de particular interés las enfermedades asociadas con la catepsina K.
EC2010009882A 2007-06-26 2010-01-15 Derivados de 1-cianociclopropilo como inhibidores de la catepsina k ECSP109882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94617807P 2007-06-26 2007-06-26
US4284008P 2008-04-07 2008-04-07

Publications (1)

Publication Number Publication Date
ECSP109882A true ECSP109882A (es) 2010-02-26

Family

ID=39761131

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009882A ECSP109882A (es) 2007-06-26 2010-01-15 Derivados de 1-cianociclopropilo como inhibidores de la catepsina k

Country Status (19)

Country Link
US (1) US8008279B2 (es)
EP (1) EP2170879B1 (es)
JP (1) JP2010531344A (es)
KR (1) KR20100039862A (es)
CN (1) CN101687864A (es)
AR (1) AR067156A1 (es)
AU (1) AU2008269513B2 (es)
BR (1) BRPI0813306A2 (es)
CA (1) CA2689945A1 (es)
CL (1) CL2008001899A1 (es)
CO (1) CO6251264A2 (es)
EC (1) ECSP109882A (es)
IL (1) IL202519A0 (es)
NZ (1) NZ581719A (es)
PE (1) PE20090841A1 (es)
RU (1) RU2470023C2 (es)
TW (1) TW200911806A (es)
UY (1) UY31180A1 (es)
WO (1) WO2009001129A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
JP5666036B2 (ja) * 2008-01-25 2015-02-04 メディベイション テクノロジーズ， インコーポレイテッド 新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
WO2010036998A2 (en) 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
US8853391B2 (en) 2008-12-18 2014-10-07 Merck Patent Gmbh Tricyclic azaindoles
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
PE20121433A1 (es) * 2009-10-21 2012-11-10 Boehringer Ingelheim Int Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
US8524703B2 (en) 2009-12-17 2013-09-03 Abbvie Inc. Bridgehead amine ring-fused indoles and indolines
US8778959B2 (en) 2009-12-17 2014-07-15 Abbvie Inc. AZA-bridged ring-fused indoles and indolines
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US8791132B2 (en) 2011-02-18 2014-07-29 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
EP2802591B1 (en) * 2012-01-11 2016-03-16 F.Hoffmann-La Roche Ag Macrocyclic amides as protease inhibitors
CN103086923B (zh) * 2013-01-21 2014-04-23 吉林大学 肼腈类组织蛋白酶k抑制剂及其在治疗骨质疏松症方面的应用
EP3055314B1 (en) * 2013-10-08 2018-09-12 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2016027285A2 (en) * 2014-08-22 2016-02-25 Alkem Laboratories Ltd. Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors
CN105837479B (zh) * 2016-04-05 2017-10-27 吉林大学 肼腈类组织蛋白酶k抑制剂及其在制备治疗骨关节炎药物中的应用
WO2018183654A1 (en) * 2017-03-29 2018-10-04 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
WO2023138695A1 (zh) * 2022-01-21 2023-07-27 山东新时代药业有限公司 一种组织蛋白酶k抑制剂与其制备方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009110A1 (en) * 1999-07-30 2001-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Novel succinate derivative compounds useful as cysteine protease inhibitors
US6525036B2 (en) * 2000-01-06 2003-02-25 Merck & Co., Inc. Compounds and compositions as protease inhibitors
AU2001245764A1 (en) 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
US7012075B2 (en) * 2001-03-02 2006-03-14 Merck & Co., Inc. Cathepsin cysteine protease inhibitors
RU2278863C2 (ru) * 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
MXPA04005263A (es) * 2001-12-04 2004-10-11 Hoffmann La Roche 2-amino-cicloalcanocarboxamidas substituidas y su uso como inhibidores de cisteina proteasa.
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
AU2003303210A1 (en) 2002-12-19 2004-07-14 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists

Also Published As

Publication number Publication date
TW200911806A (en) 2009-03-16
AU2008269513A1 (en) 2008-12-31
EP2170879A1 (en) 2010-04-07
WO2009001129A9 (en) 2010-02-04
CL2008001899A1 (es) 2009-07-17
UY31180A1 (es) 2009-01-30
CN101687864A (zh) 2010-03-31
KR20100039862A (ko) 2010-04-16
NZ581719A (en) 2011-08-26
CA2689945A1 (en) 2008-12-31
JP2010531344A (ja) 2010-09-24
US8008279B2 (en) 2011-08-30
WO2009001129A1 (en) 2008-12-31
CO6251264A2 (es) 2011-02-21
RU2010101279A (ru) 2011-08-10
RU2470023C2 (ru) 2012-12-20
AU2008269513B2 (en) 2011-06-16
AR067156A1 (es) 2009-09-30
IL202519A0 (en) 2010-06-30
US20090012077A1 (en) 2009-01-08
BRPI0813306A2 (pt) 2017-05-16
EP2170879B1 (en) 2013-01-16
PE20090841A1 (es) 2009-08-02

Similar Documents

Publication Publication Date Title
ECSP109882A (es) Derivados de 1-cianociclopropilo como inhibidores de la catepsina k
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
ECSP088456A (es) Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
ECSP11010880A (es) Compuestos orgánicos
SV2011003855A (es) Heteroarilos sustituidos
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
CR20140392A (es) Dihidropirazolonas sustituidas
CU24039B1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
CR10233A (es) Piridin-4-ilmetilamidas
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
UY31299A1 (es) Nuevos inhibidores de catepsina y su uso
EA201000329A1 (ru) Циклические депсипептиды
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
PE20151248A1 (es) Derivados de ciclopentano como inhibidores de catepsinas
ECSP088153A (es) Nuevos derivados de piperidina
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento